Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland.
To access publisher's full text version of this article click on the hyperlink below Objective: Reactive arthritis (ReA) is a spondyloarthritis triggered by a bacterial infection. In cases where nonsteroidal antiinflammatory drugs and conventional synthetic disease-modifying antirheumatic drugs...
Published in: | The Journal of Rheumatology |
---|---|
Main Authors: | , , , |
Other Authors: | |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Journal Of Rheumatology Publishing Co
2020
|
Subjects: | |
Online Access: | http://hdl.handle.net/2336/621584 https://doi.org/10.3899/jrheum.191307 |
id |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/621584 |
---|---|
record_format |
openpolar |
spelling |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/621584 2023-05-15T16:51:49+02:00 Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland. Thorsteinsson, Bjarni Geirsson, Arni J Krogh, Niels S Gudbjornsson, Bjorn 1B. Thorsteinsson, MD, Department of Medicine, and Center for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland; bjarnith@gmail.com. 2A.J. Geirsson, MD, PhD, Department of Rheumatology, Landspitali University Hospital, Reykjavik, Iceland. 3N.S. Krogh, MSc, Zitelab ApS, Copenhagen, Denmark. 2020-11 http://hdl.handle.net/2336/621584 https://doi.org/10.3899/jrheum.191307 en eng Journal Of Rheumatology Publishing Co https://www.jrheum.org/content/47/10/1575.long Thorsteinsson B, Geirsson AJ, Krogh NS, Gudbjornsson B; ICEBIO. Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland. J Rheumatol. 2020 Oct 1;47(10):1575-1581. doi:10.3899/jrheum.191307. 0315-162X 32007931 doi:10.3899/jrheum.191307 http://hdl.handle.net/2336/621584 The Journal of rheumatology Landspitali Access - LSH-aðgangur The Journal of rheumatology 47 10 1575 1581 Canada TNF-α biologics reactive arthritis registry safety Gigtarsjúkdómar Líftæknilyf Biological Products Arthritis Reactive Article 2020 ftlandspitaliuni https://doi.org/10.3899/jrheum.191307 2022-05-29T08:22:35Z To access publisher's full text version of this article click on the hyperlink below Objective: Reactive arthritis (ReA) is a spondyloarthritis triggered by a bacterial infection. In cases where nonsteroidal antiinflammatory drugs and conventional synthetic disease-modifying antirheumatic drugs have failed, biologics such as tumor necrosis factor inhibitors (TNFi) have been used. However, limited evidence exists of the efficacy and safety of these drugs in ReA. We report on Icelandic patients with ReA who have been treated with TNFi, their characteristics, outcomes, and safety. Methods: We conducted an observational cohort study using the Icelandic nationwide database of biologic therapy (ICEBIO) supplemented with a retrospective study of electronic health record (EHR) data. Drug efficacy was assessed using disease activity scores and standardized questionnaires within ICEBIO; safety was assessed using ICEBIO and EHR data. Results: Thirty-eight patients with ReA were registered in the database. Eight were given TNFi within 1 year of symptom onset. At 6 and 18 months, there was a significant reduction in C-reactive protein (CRP), tender and swollen joints, visual analog scale for pain and fatigue, 28-joint count Disease Activity Score 28 based on CRP, Clinical Disease Activity Index, and Health Assessment Questionnaire scores. Seventy-one to 90% of patients were considered treatment responders. Two patients were able to stop biologics owing to remission. During the 303 patient-years (mean 8, range 1-15) biologics were given, 6 hospital admissions for infections were noted. Conclusion: TNFi are safe and effective in ReA, but treatment tends to be prolonged. Further clinical trials are urgently needed in ReA. Keywords: TNF-α; biologics; reactive arthritis; registry; safety. Article in Journal/Newspaper Iceland Hirsla - Landspítali University Hospital research archive The Journal of Rheumatology 47 10 1575 1581 |
institution |
Open Polar |
collection |
Hirsla - Landspítali University Hospital research archive |
op_collection_id |
ftlandspitaliuni |
language |
English |
topic |
TNF-α biologics reactive arthritis registry safety Gigtarsjúkdómar Líftæknilyf Biological Products Arthritis Reactive |
spellingShingle |
TNF-α biologics reactive arthritis registry safety Gigtarsjúkdómar Líftæknilyf Biological Products Arthritis Reactive Thorsteinsson, Bjarni Geirsson, Arni J Krogh, Niels S Gudbjornsson, Bjorn Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland. |
topic_facet |
TNF-α biologics reactive arthritis registry safety Gigtarsjúkdómar Líftæknilyf Biological Products Arthritis Reactive |
description |
To access publisher's full text version of this article click on the hyperlink below Objective: Reactive arthritis (ReA) is a spondyloarthritis triggered by a bacterial infection. In cases where nonsteroidal antiinflammatory drugs and conventional synthetic disease-modifying antirheumatic drugs have failed, biologics such as tumor necrosis factor inhibitors (TNFi) have been used. However, limited evidence exists of the efficacy and safety of these drugs in ReA. We report on Icelandic patients with ReA who have been treated with TNFi, their characteristics, outcomes, and safety. Methods: We conducted an observational cohort study using the Icelandic nationwide database of biologic therapy (ICEBIO) supplemented with a retrospective study of electronic health record (EHR) data. Drug efficacy was assessed using disease activity scores and standardized questionnaires within ICEBIO; safety was assessed using ICEBIO and EHR data. Results: Thirty-eight patients with ReA were registered in the database. Eight were given TNFi within 1 year of symptom onset. At 6 and 18 months, there was a significant reduction in C-reactive protein (CRP), tender and swollen joints, visual analog scale for pain and fatigue, 28-joint count Disease Activity Score 28 based on CRP, Clinical Disease Activity Index, and Health Assessment Questionnaire scores. Seventy-one to 90% of patients were considered treatment responders. Two patients were able to stop biologics owing to remission. During the 303 patient-years (mean 8, range 1-15) biologics were given, 6 hospital admissions for infections were noted. Conclusion: TNFi are safe and effective in ReA, but treatment tends to be prolonged. Further clinical trials are urgently needed in ReA. Keywords: TNF-α; biologics; reactive arthritis; registry; safety. |
author2 |
1B. Thorsteinsson, MD, Department of Medicine, and Center for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland; bjarnith@gmail.com. 2A.J. Geirsson, MD, PhD, Department of Rheumatology, Landspitali University Hospital, Reykjavik, Iceland. 3N.S. Krogh, MSc, Zitelab ApS, Copenhagen, Denmark. |
format |
Article in Journal/Newspaper |
author |
Thorsteinsson, Bjarni Geirsson, Arni J Krogh, Niels S Gudbjornsson, Bjorn |
author_facet |
Thorsteinsson, Bjarni Geirsson, Arni J Krogh, Niels S Gudbjornsson, Bjorn |
author_sort |
Thorsteinsson, Bjarni |
title |
Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland. |
title_short |
Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland. |
title_full |
Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland. |
title_fullStr |
Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland. |
title_full_unstemmed |
Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland. |
title_sort |
outcomes and safety of tumor necrosis factor inhibitors in reactive arthritis: a nationwide experience from iceland. |
publisher |
Journal Of Rheumatology Publishing Co |
publishDate |
2020 |
url |
http://hdl.handle.net/2336/621584 https://doi.org/10.3899/jrheum.191307 |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
The Journal of rheumatology 47 10 1575 1581 Canada |
op_relation |
https://www.jrheum.org/content/47/10/1575.long Thorsteinsson B, Geirsson AJ, Krogh NS, Gudbjornsson B; ICEBIO. Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland. J Rheumatol. 2020 Oct 1;47(10):1575-1581. doi:10.3899/jrheum.191307. 0315-162X 32007931 doi:10.3899/jrheum.191307 http://hdl.handle.net/2336/621584 The Journal of rheumatology |
op_rights |
Landspitali Access - LSH-aðgangur |
op_doi |
https://doi.org/10.3899/jrheum.191307 |
container_title |
The Journal of Rheumatology |
container_volume |
47 |
container_issue |
10 |
container_start_page |
1575 |
op_container_end_page |
1581 |
_version_ |
1766041940583776256 |